Study Finds CBD Associated with PTSD Symptom
Reduction in Adults with PTSD
LAS VEGAS, May 14, 2019 (GLOBE NEWSWIRE) --
CV Sciences, Inc.
(CVSI) (the âCompanyâ, âCV Sciencesâ,
âourâ, âusâ or âweâ), a preeminent supplier and manufacturer of
hemp cannabidiol (CBD) products, is pleased to announced that its
industry-dominating PlusCBD Oilâ¢ products
were used in the first study to date examining the clinical benefit
of CBD for the treatment of Post-Traumatic Stress Disorder
The study, published in The Journal of Alternative
and Complementary Medicine in April 2019,
examined the effect of oral CBD administration on symptoms of PTSD
in a series of 11 adult patients at an outpatient psychiatry
clinic. CV Sciences provided various PlusCBD Oil products for the
study; delivery systems and usage were determined by patient and
provider preference. The published study can be viewed at the
following link: Cannabidiol in the
Treatment of Post-Traumatic Stress Disorder: A Case Series. CV
Sciences was not involved in the data collection, data
interpretation, the preparation of the article, or the decision to
submit for publication.
CBD was given on an open-label, flexible dosing
regimen to patients diagnosed with PTSD by a mental health
professional. Patients also received routine psychiatric care,
including concurrent treatment with psychiatric medications and
psychotherapy. The length of the study was eight weeks.
From the total sample of 11 patients, 10
experienced a decrease in PTSD symptom severity. The study
concluded that administration of oral CBD in addition to routine
psychiatric care was associated with PTSD symptom reduction in
adults with PTSD. CBD also appeared to offer relief in a subset of
patients who reported frequent nightmares as a symptom of their
âWe were impressed with the improvements seen in
the subjects. These findings can help inform future clinical
investigations, including double blind, placebo-controlled trials,
to confirm the response to CBD that was observed in this study, â
says Scott Shannon, MD, principal investigator in the study.
âCV Sciences continued commitment to furthering
scientific research allows us to better understand the benefits of
CBD or a wide range of indications,â said Joseph Dowling, Chief
Executive Officer. âAfter more than 80 years of prohibition,
hemp CBD research has been severely hindered, but with the passage
of the 2018 Farm Bill, we are beginning to understand the clinical
benefits of CBD through scientific rigor. While we recognize
that dietary supplements canât be marketed for treating disease, we
are pleased to support scientific progress by providing our PlusCBD
Oilâ¢ products to researchers and look forward to continued research
on the clinical benefits of CBD for patients with PTSD and other
About CV Sciences, Inc.
CV Sciences, Inc.
(CVSI) operates two distinct business
segments: a consumer product division focused on manufacturing,
marketing and selling plant-based CBD products to a range of market
sectors; and a drug development division focused on developing and
commercializing CBD-based novel therapeutics utilizing CBD. The
Companyâs PlusCBD Oilâ¢ is the
top-selling brand of hemp-derived CBD on the market, according to
SPINS, the leading provider of syndicated data and insights for the
natural, organic and specialty products industry. CV Sciences, Inc.
has primary offices and facilities in San Diego, California and Las
Vegas, Nevada. Additional information is available from
OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain
forward-looking statements and information, as defined within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and is subject to the
Safe Harbor created by those sections. This material contains
statements about expected future events and/or financial results
that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements by definition
involve risks, uncertainties.
Scott Van Winkle